Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc.（APGE）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · APGE · 截至 2026年6月8日
活动摘要
买入笔数
1
P-Purchase only
卖出笔数
78
近12个月
买卖比
0.01
Buy/Sell (by trades)
整体情绪
Apogee Therapeutics, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
APGE 季度内部人买卖趋势
APGE 内幕交易卖出 · APGE 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · APGE CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
APGE 高管卖出股份 · APGE 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jun 3, 2026 | Dambkowski Carl Chief Medical Officer | Option | 4,125 | $94K | Form 4 |
| Jun 3, 2026 | Dambkowski Carl Chief Medical Officer | Sale | 5,500 | $433K | Form 4 |
| May 13, 2026 | HENDERSON MICHAEL THOMAS CEO · Director | Sale | 18,659 | $1.53M⚡ | Form 4 |
| May 13, 2026 | HENDERSON MICHAEL THOMAS CEO · Director | Sale | 1,341 | $111K | Form 4 |
| May 6, 2026 | Dambkowski Carl Chief Medical Officer | Option | 4,125 | $94K | Form 4 |
| May 6, 2026 | Dambkowski Carl Chief Medical Officer | Sale | 3,700 | $311K | Form 4 |
| May 6, 2026 | Dambkowski Carl Chief Medical Officer | Sale | 1,800 | $152K | Form 4 |
| May 1, 2026 | Henderson Jane CFO | Sale | 811 | $66K | Form 4 |
| May 1, 2026 | Henderson Jane CFO | Sale | 900 | $74K | Form 4 |
| May 1, 2026 | Henderson Jane CFO | Sale | 289 | $24K | Form 4 |
| Apr 16, 2026 | HENDERSON MICHAEL THOMAS CEO · Director | Option | 3,000 | $69K | Form 4 |
| Apr 16, 2026 | Henderson Jane CFO | Sale | 2,000 | $180K | Form 4 |
| Apr 8, 2026 | HENDERSON MICHAEL THOMAS CEO · Director | Sale | 17,800 | $1.47M⚡ | Form 4 |
| Apr 8, 2026 | HENDERSON MICHAEL THOMAS CEO · Director | Sale | 2,000 | $167K | Form 4 |
| Apr 8, 2026 | HENDERSON MICHAEL THOMAS CEO · Director | Sale | 200 | $17K | Form 4 |
| Apr 1, 2026 | Dambkowski Carl Chief Medical Officer | Option | 4,125 | $94K | Form 4 |
| Apr 1, 2026 | Dambkowski Carl Chief Medical Officer | Sale | 2,698 | $227K | Form 4 |
| Apr 1, 2026 | Dambkowski Carl Chief Medical Officer | Sale | 2,702 | $231K | Form 4 |
| Apr 1, 2026 | Dambkowski Carl Chief Medical Officer | Sale | 100 | $9K | Form 4 |
| Apr 1, 2026 | Henderson Jane CFO | Sale | 900 | $76K | Form 4 |
| Apr 1, 2026 | Henderson Jane CFO | Sale | 1,100 | $94K | Form 4 |
| Mar 25, 2026 | Henderson Jane CFO | Sale | 2,000 | $170K | Form 4 |
| Mar 11, 2026 | HENDERSON MICHAEL THOMAS CEO · Director | Sale | 8,363 | $621K | Form 4 |
| Mar 11, 2026 | HENDERSON MICHAEL THOMAS CEO · Director | Sale | 8,219 | $615K | Form 4 |
| Mar 11, 2026 | HENDERSON MICHAEL THOMAS CEO · Director | Sale | 3,418 | $259K | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 APGE 内幕交易
APGE 内幕交易
Apogee Therapeutics, Inc.（APGE）内幕交易数据来源于公司内部人（包括Dambkowski Carl (Chief Medical Officer), HENDERSON MICHAEL THOMAS (CEO · Director), Henderson Jane (CFO)）提交的SEC Form 4申报文件。过去12个月内，4位内部人向SEC提交了交易申报。APGE内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Apogee Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
APGE 内幕交易 · 5个问题Apogee Therapeutics, Inc.（APGE）的内部人包括高管和董事，如Dambkowski Carl (Chief Medical Officer), HENDERSON MICHAEL THOMAS (CEO · Director), Henderson Jane (CFO)等。过去12个月内，4位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026